Honorees were recognized for making strides in advancing the treatment of gastrointestinal cancers.
Richard M. Goldberg, M.D., retired in December 2019 as the director of the West Virginia University Cancer Institute (WVUCI) and the WVU Cancer Signature Program. As WVUCI’s director, he oversaw the clinical, research, and teaching missions of the cancer institute and its component organizations, which include satellite clinical and clinical research locations dispersed throughout West Virginia. Following his retirement, he plans to continue to play a supportive role in mentoring faculty and serving as a resource to the Cancer Institute’s leadership. He and his wife, Lynda, expect to continue to reside in Morgantown.
Considered an international leader in gastrointestinal cancer treatment and research as well as in leadership of cancer programs in academic medicine, Dr. Goldberg has been principal investigator, co-PI, co-investigator and mentor on multiple research and training grants funded through the National Cancer Institute (NCI). He has published more than 347 papers in peer-reviewed journals and been the author of 26 book chapters. His clinical interests are in the management of patients with malignancies in the gastrointestinal tract.
“It has been a distinct honor and privilege to lead this growing Institute that will continue to grow into the future,” Goldberg said. “We have recruited a vibrant group of new faculty members and other professionals who support the clinical, educational, and research missions and this has been recognized by increasing national prominence and patient demand for our clinical services. I know the WVU Cancer Institute will continue to grow in stature and be an integral part of WVU and WVU Medicine.”
His research focused on defining new treatments, elucidating inherited cancer susceptibility, and identification of predictive and prognostic factors in GI cancers. He helps to lead the Alliance for Clinical Trials in Oncology as the Associate Group Chair of this NCI funded organization that is a member of the National Clinical Trials Network. The Alliance conducts clinical trials and does translational research across the US and Canada.
He is a graduate of Harvard University, earning an undergraduate degree cum laude in biology in 1975 and received his medical degree from the State University of New York Upstate Medical University in 1989 where he was elected to the Alpha Omega Alpha honor medical society.
Prior to his arrival at WVU in 2017, he served as physician in chief of both the James Cancer Hospital at The Ohio State University (OSU) and, prior to that of the North Carolina Cancer Hospital at the UNC in Chapel Hill (UNC). He was an Associate Director at both the OSU the UNC Comprehensive Cancer Centers and the Division Chief of Hematology and Oncology at UNC and Acting Division Director of Medical Oncology at OSU. Prior to that, he was a consultant at the Mayo Clinic in Rochester and Associate Chair of the Department of Medicine at the Geisinger Clinic in Danville, PA.
OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with current and insightful information on patient care, in conjunction with The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers, honored five individuals with a 2020 Luminary Award in GI Cancers for their commitment to the GI cancer community. The Luminary Awards in GI Cancers event recognizing this year’s honorees will take place this Fall in tandem with the 2020 Ruesch Center Symposium.
“Congratulations to the 2020 Luminary Awards in GI Cancers honorees,” said Mike Hennessy Jr., president, and CEO of MJH Life Sciences™, the parent company of OncLive®. “All five of these individuals have influenced the field of GI cancers tremendously through research, clinical care and advocating for patients. We are so proud that we were able to collaborate with The Ruesch Center to celebrate these dedicated individuals, who make a difference every day by improving the lives of patients with gastrointestinal cancers.”
Other Honorees Included:
Gayle S. Jameson, MSN, RN, ACNP-BC, AOCN, is a nurse practitioner who has cared for adults living with cancer for more than 40 years.
Stacie C. Lindsey is the chief executive officer and founder of the Cholangiocarcinoma Foundation. Lindsey established the foundation in 2006 to help find a cure for cholangiocarcinoma (bile duct cancer) and improve the quality of life for those affected by the disease through advocacy, education, collaboration and research.
Tyvin Rich, M.D., FACR, is a radiation oncologist at the Hampton University Proton Therapy Institute and professor emeritus at the University of Virginia. Rich has spent his career involved with the use and development of agents that are used as radiation sensitizers, particularly for GI cancers.
Diane M. Simeone, M.D., is an internationally recognized surgeon and scientist serving as the director of the Pancreatic Cancer Center at New York University (NYU) Langone Health, associate director of translational research at Perlmutter Cancer Center and the Laura and Isaac Perlmutter Professor of Surgery at NYU Langone Health.
"The Luminaries Awards is our opportunity to honor those who have set a standard for us all. Each awardee's dedication, creativity, compassion, and laser-like focus on improving outcomes for GI cancer patients has translated into new standards. We give these awards to recognize their efforts and to inspire others as we continue in the fight," said John L. Marshall, M.D., director, The Ruesch Center for the Cure of GI Cancers.
About the Ruesch Center for the Cure of Gastrointestinal Cancers
The Ruesch Center for the Cure of Gastrointestinal Cancers is part of the Georgetown Lombardi Comprehensive Cancer Center. It focuses on personalized patient care and fighting against gastrointestinal cancers. The Ruesch Center provides the highest standard of care and individualized cures through clinical trials and research, education and advocacy, and regional and global alliances.
A digital platform of resources for practicing oncologists, OncLive® offers oncology professionals information they can use to help provide the best patient care. OncLive® is a brand of MJH Life Sciences™, the largest privately held, independent, a full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.
OncLive® Media Contact
John Patricolo, 609-325-4630
Abraham Kanate, MD, Medical Director for the Osborn Hematopoietic Malignancy and Cellular Therapy Program and Associate Professor recently led the consensus guidelines from the American Society of Transplant and Cellular Therapy (ASTCT) on indications for transplant and cellular therapy.
Starting the week of March 30, virtual exercise classes, wellbeing and mindfulness programs will be available to WVU and WVU Medicine employees.